Table 1

Demographics of patients receiving 105AD7 prior to surgery

Patient no	Sex	Age at time of removal of primary tumour (y)	Site of tumour	Differentiation of primary tumour	Dukes’ stage	Dose of 105AD7 (μg)	Immunohistochemical analysis of tumour sections	TIL
1	Female	75	Rectum	Moderate	C	10 + 50	Yes	Yes
2	Female	79	Sigmoid	Moderate	B	10 + 50	Yes	Yes
3	Male	82	Caecum	Moderate	C	10 + 50	Yes	Yes
4	Male	87	Caecum	Moderate	B	10 + 50	Yes	No
5	Male	75	Rectum	Moderate	A	10 + 50	Yes	Yes
6	Male	73	Rectum	Moderate	C	50 + 50	Yes	Yes
7	Male	70	Rectum	Moderate	B	50 + 50	Yes	No
8	Male	56	Rectum	Moderate	B	50 + 50	Yes	Yes
9	Female	67	Rectum	Moderate	A	50 + 50	Yes	Yes
10	Female	62	Rectum	Poor	C	50 + 50	Yes	Yes
11	Male	58	Rectum	Moderate	A	50 + 50	Yes	Yes
12	Male	76	Sigmoid	Moderate	A	50 + 50	Yes	Yes
13	Female	67	Ascending	Poor	B	10 + 100	Yes	No
14	Male	67	Sigmoid	Moderate	A	10 + 100	Yes	No
15	Female	82	Rectum	Moderate	C	10 + 100	Yes	No
16	Male	75	Rectum	Moderate	D	10 + 50^1-150	Yes	Yes
17	Male	63	Rectum	Moderate	C	50 + 50	No	Yes
18	Male	75	Rectum	Moderate	B	10 + 20	No	Yes
19	Female	63	Rectum	Moderate	B	10 + 50	No	Yes